Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Abstract

We examined the effects of metformin on diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS During the DPP (1996-2001), adults at high risk of developing diabetes were randomly assigned to masked placebo (n = 1,082) or metformin 850 mg twice daily (n = 1,073). Participants originally assigned to metformin continued to receive metformin, unmasked, in the DPPOS (2002-present). Ascertainment of diabetes development was based on fasting or 2-h glucose levels after an oral glucose tolerance test or on HbA 1c. Reduction in diabetes incidence with metformin was compared with placebo in subgroups by hazard ratio (HR) and rate differences (RDs). RESULTS During 15 years of postrandomization follow-up, metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or 36% based on glucose or HbA 1c levels, respectively. Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD 24.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD 20.38 cases/100 person-years [interaction P = 0.03 for HR, P = 0.01 for RD]). Metformin also had greater effects, by HR and RD, at higher baseline fasting glucose levels. With diabetes development based on HbA 1c , metformin was more effective in subjects with higher baseline HbA 1c by RD, with metformin RD 21.03 cases/100 person-years with baseline HbA 1c <6.0% (42 mmol/mol) and 23.88 cases/100 person-years with 6.0-6.4% (P = 0.0001). CONCLUSIONS Metformin reduces the development of diabetes over 15 years. The subsets that benefitted the most include subjects with higher baseline fasting glucose or HbA 1c and women with a history of GDM.

Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects

“…In our 21-day study, fasting plasma glucose decreased by 5.9% and fasting insulin decreased by 38%. In a 15-year study, metformin reduced the incidence of diabetes compared to placebo by 17% and the subset that benefited most included subjects with higher baseline plasma glucose or A1c (49). Our data illustrate a similar trend and we have supporting evidence (50) that DEA will be even more effective in more advanced diabetic pathology.…”

Reversing Type 2 Diabetes: A Narrative Review of the Evidence

“…While the exact criteria are still debated, most agree that a hemoglobin A1c (HbA1c) under the diabetes threshold of 6.5% for an extended period of time without the use of glycemic control medications would qualify [6]. Excluding metformin from the glycemic control medications list, as it has indications beyond diabetes, may also be a consideration [7,8]. Likewise, terms such as “partial” (HbA1c <6.5 without glycemic control medications for 1 year) or “complete” (HbA1c <5.7 without glycemic control medications for 1 year) remission have been defined by an expert panel as more evidence accumulates that points to the possibility of avoiding the presumably progressive nature of T2D [9].…”

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort

“…The largest and longest trial in general population at high risk of developing type 2 diabetes (T2D) included 3234 participants with impaired glucose tolerance, elevated fasting plasma glucose and BMI of ≥24 kg/m 2 , and metformin reduced the incidence of T2D by 31% compared with placebo after an average follow-up of 2.8 years and by 18% over 10 and 15 years post randomization (10). The subgroups that benefited the most included subjects with obesity, higher baseline fasting glucose or HbA1c and women with history of gestational diabetes mellitus (10,11). Furthermore, a recent systemic review demonstrated that adults using metformin experienced and maintained greater decreases in weight/BMI when compared with subjects on placebo, irrespective of duration of intervention and of the prescribed daily dosage (12).…”